Xalkori


What it is used for

XALKORI is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).,XALKORI is indicated for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 30 degrees Celsius
  • Store at room temperature
  • Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 30 degrees Celsius
  • Store at room temperature
  • Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient crizotinib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.


Visual appearance

Hard gelatin capsule with pink opaque body and cap, printed with black ink Pfizer on the cap, CRZ 250 on the body.


Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments